Carcinogenesis Advance Access originally published online on January 16, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis, Vol. 25, No. 6, 967-971,
June 2004
Carcinogenesis vol.25 no.6 © Oxford University Press 2004; all rights reserved.
ARTICLE |
The prostate 25-hydroxyvitamin D-1
-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D
1 Section of Endocrinology, Diabetes and Nutrition, Boston University School of Medicine, Boston, MA 02118, USA, 2 Department of Cancer Biology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA and 3 Department of Urology, University of Miami School of Medicine, Miami, FL 33101, USA
4 To whom correspondence should be addressed at Room M-1022, Boston University Medical Center, 715 Albany Street, Boston, MA 02118, USA Email: taichen{at}bu.edu
The hormonal form of vitamin D, 1
,25-dihydroxyvitamin D [1,25(OH)2D] promotes the differentiation and inhibits the proliferation, invasiveness and metastasis of prostate cells. However, 1,25(OH)2D is not suitable as a chemopreventive agent because its administration can cause hypercalcemia. Serum levels of 1,25(OH)2D are tightly regulated by the renal enzyme, 25-hydroxyvitamin D-1-hydroxylase (1-OHase), which synthesizes 1,25(OH)2D from the prohormone, 25-hydroxyvitamin D [25(OH)D]. Normal prostate epithelial cells in primary culture, as well as several prostate cancer cell lines, also express 1-OHase and synthesize the hormone intracellularly. We now investigated the regulation of the prostate 1-OHase by the three most important regulators of the renal 1-OHase: calcium, 1,25(OH)2D and parathyroid hormone (PTH). The 1-OHase activity in the primary cultures of prostate epithelial cells was inhibited by 1,25(OH)2D3 at 10 and 100 nM, whereas PTH at 10 and 100 nM had no significant effect. Calcium at 1.2 and 2.4 mM had no significant effect on the enzyme activity in the PZ-HPV-7 cell line, a prostate epithelial cell line derived from normal prostate tissue. Conversely, 1.2 or 2.4 mM calcium markedly inhibited 1-OHase activity in a human kidney cell line used as a positive control. Furthermore, PTH at 100 nM and calcium at 1.2 and 2.4 mM had no effect on the 1-OHase gene promoter activity in prostate cells, whereas the promoter activity was inhibited 48 ± 5% by 100 nM 1,25(OH)2D3. Our findings suggest that, unlike the renal enzyme, the prostate 1-OHase appears to be largely unregulated by serum levels of PTH and calcium. These findings support the hypothesis that vitamin D or 25(OH)D may be useful as chemopreventive agents for prostate cancer because their administration should cause an increased synthesis of 1,25(OH)2D within prostate cells.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. C. Fleet, C. Gliniak, Z. Zhang, Y. Xue, K. B. Smith, R. McCreedy, and S. A. Adedokun Serum Metabolite Profiles and Target Tissue Gene Expression Define the Effect of Cholecalciferol Intake on Calcium Metabolism in Rats and Mice J. Nutr., June 1, 2008; 138(6): 1114 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Urushino, S. Nakabayashi, M. A. Arai, A. Kittaka, T. C. Chen, K. Yamamoto, K. Hayashi, S. Kato, M. Ohta, M. Kamakura, et al. Kinetic Studies of 25-Hydroxy-19-nor-vitamin D3 and 1{alpha},25-Dihydroxy-19-nor-vitamin D3 Hydroxylation by CYP27B1 and CYP24A1 Drug Metab. Dispos., September 1, 2007; 35(9): 1482 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. McCarty and K. I. Block Toward a core nutraceutical program for cancer management. Integr Cancer Ther, June 1, 2006; 5(2): 150 - 171. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Teegarden, P. Legowski, C. W. Gunther, G. P. McCabe, M. Peacock, and R. M. Lyle Dietary Calcium Intake Protects Women Consuming Oral Contraceptives from Spine and Hip Bone Loss J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5127 - 5133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. McCarty Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380. [Abstract] [PDF]
|
|